Tandakha Dieye

Tandakha Dieye


University Cheikh Anta Diop (UCAD), Le Dantec Hospital, IRESSEF, Senegal

Tel: +221 776577054

Email: Tandakha.dieye@ucad.edu.sn, Tandakha.Dieye@iressef.org, tndieye@yahoo.co.uk





Network Investigator


Research Keywords: 

Immunology, Vaccines



Full Professor in immunology and vaccinology in Cheikh Anta Diop University (UCAD) since 2006. Dr Dieye is currently headed the immunology platform in Le Dantec University teaching hospital (Dakar) and in IRESSEF (Diamniadio, Dakar). Dr Dieye is also head of the National blood transfusion laboratories. He is acting President of the African Society for Immunodeficiencies (ASID). His main activities are focusing on TB, HIV, Malaria, neglected diseases (schistosomiasis) and re-emergent disease (EBOLA) immune responses. He is also WHO expert member of the Technical Advisory Group (TAG) for measles & rubella, member of the Senegalese NITAG and facilitator of the WHO regional Vaccinology course in Africa. Recently he is nominated as a member of WHO Regional Verification Committee (RVC) for measles elimination in Africa. As Immunology investigator on vaccine research, he managed many vaccine trials including TB Phase I and Phase II, Malaria Phase II and EBOLA vaccine Phases I and II.


Related Websites: 

ResearchGate Profile


Key Publications:

  • Mbengue MAS, Sarr M, Faye A, Badiane O, Camara FBN, Mboup S, Dieye TN. Determinants of complete immunization among Senegalese children aged 12-23 months evidence from the demongraphic and health survey. BMC Public Health. 2017 Jul 6; 17(1):630.
  • Sall A, Touré AO, Sall FB, Ndour M, Fall S, Sène A, Faye BF, Seck M, Gadji M, Dièye TN, Mathiot C, Reynaud S, Diop S, Raphaël M. Characteristics of chronic lymphocytic leukemia in Senegal. BMC Hematol. 2016;16 :10. 
  • Bousfiha AA, Jeddane L, Erwa N, Dieye TN, Mellouli F, Reda SM, Esser M, Boukari R. Development of Primary Immunodeficiencies in Africa.J Clin Immunol. 2015 May;35(4):329-30.
  • BP Ndiaye, F Thienemann, MO, BS Landry, M Camara, S Dièye, Dieye TN, H Esmail, R Goliath, K Huygen, V January, I Ndiaye, T Oni, M Raine, M Romano, I Satti, S Sutton,A Thiam, KA Wilkinson,  S Mboup, R J Wilkinson, H McShane. Safety, immunogenicity and efficacy of the candidate tuberculosis vaccine MVA85A in healthy HIV-infected adults: A randomized, placebo-controlled phase 2 trial. Lancet Respiratory Medicine. 2015, Mar; 3(3):190-200.
  • Bei AK, Diouf A, Miura K, Larremore DB, Ribacke U, Tullo G, Moss EL, Neafsey DE, Daniels RF, Zeituni AE, Nosamiefan I, Volkman SK, Ahouidi AD, Ndiaye D, Dieye T, Mboup S, Buckee CO, Long CA, Wirth DF.  Immune characterization of P falciparum parasites with a shared genetic signature in a region of decreasing transmission. Infect Immun. 2015 Jan;83(1):276-85.
  • Dieye TN, Ndiaye BP, Dieng AB, Fall M, Britain N, Vermaak S, Camara M, Diop-Ndiaye H, Ngom-Gueye NF, Diaw PA, Toure-Kane C, Sow PS, Mboup S, McShane H.  Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects. PLoS One. 2013 Jun 28;8(6):
  • Jennes W, Verheyden S, Mertens JW, Camara M, Seydi M, Dieye TN, Mboup S, Demanet C, Kestens L. Inhibitory KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission; Blood 2013; 121 (7): 1157-64.
  • Mbow M, Larkin BM, Meurs L, Wammes LJ, de Jong SE, Labuda LA, Camara M, Smits HH, Polman K, Dieye TN, Mboup S, Stadecker MJ, Yazdanbakhsh M. Th17 cells are associated with pathology in human schistosomiasis. J Infect Dis. 2012 Oct 19.
  • Camara M, Dieye TN, Seydi M, Diallo AA, Fall M, Diaw PA, Sow PS, Mboup S, Kestens L, Jennes W.Low-level CD4+ T cell activation in HIV-exposed seronegative subjects: influence of gender and condom use. J Infect Dis.2010 Mar 15;201(6):835-42.
  • Dieye T.N., Sow P.S., Simonart T., Gueye-Ndiaye A., Popper S.J., Delforge M.L., Dieye A., Sarr A.D., Crusiaux A., Vooren J.P., Devleeschouwer M., Kanki P., Mboup S., Diakhate L., Farber C-M. Immunologic and virologic response after tetanus toxoid booster among HIV-1 and HIV-2 infected Senegalese  individuals. Vaccine2001; 20 (5-6): 905 – 913.